Accelerating the Alzheimer’s disease patient journey with AI-powered disease detection and care coordination

Schedule a meeting
Two smartphone screens showing MRI scans of the human brain
Picture collage of two doctors discussing patient scans, and a doctor discussing diagnosis with a patient.

Leading pharma companies need to adapt to changing diagnostic and monitoring practices

Challenges in Prediction, Detection, and Monitoring
Predicting and detecting Alzheimer’s disease in its early stages proves to be challenging due to the disease’s subtle progression without prominent initial symptoms. This complexity in early detection inhibits definitive diagnosis and timely intervention. Furthermore, new Alzheimer’s therapies aimed at slowing cognitive decline require periodic monitoring for amyloid related imaging abnormalities (ARIA) on MRI scans, adding another layer of complexity to Alzheimer’s management.

Navigating Imaging and Therapy Access
Streamlining worklists and communication between treating neurologists and neuroradiologists is crucial in accelerating access to Alzheimer’s therapies. This is where Viz.ai excels.

Optimize HCP workflows. Enhance patient care.

Viz.ai’s AI-powered solutions facilitate every step of the patient journey at the point-of-care, increasing access to life-saving treatments. As a pioneer in advancing detection and care coordination for millions of patients with neurological conditions – including stroke, aneurysm, and hemorrhage – Viz.ai delivers significant value to patients, providers, and pharma partners.

Predict

Leverage the power of AI to analyze clinical data and imaging across healthcare systems, enabling early identification of patients.

Detect

Utilize AI and HIPAA-compliant communication tools to auto-detect suspected Alzheimer’s disease and associated risk-factors, ensuring care activation and next-best-action.

Monitor

Efficiently monitor patients at scale, tracking longitudinal disease progression, risk-factors, and treatment response.

Case Study as a Leader in Cerebral Aneurysm

FDA-cleared Viz Aneurysm software automatically detects suspected cerebral aneurysms and triages patients for proper monitoring and treatment.

28%

increase

Unruptured cerebral aneurysm detection (≥4mm)1

67%

increase

Patients eligible for follow-up1

2.2x

increase

Treatable aneurysms (>7mm)1

Discover how Viz.ai can support you in predicting, detecting, and monitoring Alzheimer's disease in this new era of therapy

Schedule a meeting

The Proven Care Coordination Platform

Trusted by

1500+

hospitals with users across many specialties and disease areas

Screening 1 patient every

12

seconds

>90%

of alerts viewed within 5 minutes

Backed by robust clinical evidence with

100+

publications and abstracts

Schedule a meeting

Experience the power of AI

See for yourself how you can harness the power of AI to accelerate patient access to care through AI-powered care coordination.

1 Kim HW, et al. Machine learning–enabled detection of Unruptured cerebral aneurysms improves detection rates and clinical care. Stroke Vasc Interv Neurol. Published online 2023. doi:10.1161/svin.123.000938